Gene · 2122
Papers2,623
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 2,623
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Aberrant ecotropic viral integration site-1 (EVI-1) and myocyte enhancer factor 2 C gene (MEF2C) in adult acute myeloid leukemia are associated with adverse t (9:22) & 11q23 rearrangements. | Ann Hematol | 2024 | 38710877 | PubTator, text mining | PubMed |
| A liquid biopsy assay for the noninvasive detection of lymph node metastases in T1 lung adenocarcinoma. | Thorac Cancer | 2024 | 38682829 | PubTator, text mining | PubMed |
| (Sialyl)Lewis Antigen Expression on Glycosphingolipids, N-, and O-Glycans in Colorectal Cancer Cell Lines is Linked to a Colon-Like Differentiation Program. | Mol Cell Proteomics | 2024 | 38670309 | PubTator, text mining | PubMed |
| High throughput screening aids clinical decision-making in refractory acute myeloid leukaemia. | Cancer Rep (Hoboken) | 2024 | 38662349 | PubTator, text mining | PubMed |
| Proceedings of the CIMAGO Congress - Environment, Genetics and Oncobiology in the 21st Century - Challenges and Opportunities. | Medicine (Baltimore) | 2024 | 38579039 | PubTator, text mining | PubMed |
| MECOM: a bioinformatics and experimentally identified marker for the diagnosis and prognosis of lung adenocarcinoma. | Biomark Med | 2024 | 38440890 | PubTator, text mining | PubMed |
| The ETV6-MECOM fusion protein promotes EMT-related properties by repressing the transactivation activity of E-cadherin promoter in K562 leukemia cells. | Biochem Biophys Rep | 2024 | 38405662 | PubTator, text mining | PubMed |
| Directed Differentiation of Human Induced Pluripotent Stem Cells to Heart Valve Cells. | Circulation | 2024 | 38357822 | PubTator, text mining | PubMed |
| Genetic Analysis of Obstructive Sleep Apnea and Its Relationship with Severe COVID-19. | Ann Am Thorac Soc | 2024 | 38330144 | PubTator, text mining | PubMed |
| Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM). | Blood Cancer J | 2024 | 38316746 | PubTator, text mining | PubMed |
| Promoter-centred chromatin interactions associated with EVI1 expression in EVI1+3q- myeloid leukaemia cells. | Br J Haematol | 2024 | 38296260 | PubTator, text mining | PubMed |
| Allogenic hematopoietic stem cell transplantation outcomes of patients aged ≥ 55 years with acute myeloid leukemia or myelodysplastic syndromes in China: a retrospective study. | Stem Cell Res Ther | 2024 | 38282037 | PubTator, text mining | PubMed |
| A novel missense mutation in the MECOM gene in a Chinese boy with radioulnar synostosis with amegakaryocytic thrombocytopenia. | BMC Pediatr | 2024 | 38245683 | PubTator, text mining | PubMed |
| The multifaceted role of Fragile X-Related Protein 1 (FXR1) in cellular processes: an updated review on cancer and clinical applications. | Cell Death Dis | 2024 | 38238286 | PubTator, text mining | PubMed |
| Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes. | Ther Adv Hematol | 2024 | 38186638 | PubTator, text mining | PubMed |
| An aging-related immune landscape in the hematopoietic immune system. | Immun Ageing | 2024 | 38169405 | PubTator, text mining | PubMed |
| Genome-wide association study of preserved ratio impaired spirometry (PRISm). | Eur Respir J | 2024 | 38097206 | PubTator, text mining | PubMed |
| Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. | Leukemia | 2024 | 38086946 | PubTator, text mining | PubMed |
| HYENA detects oncogenes activated by distal enhancers in cancer. | bioRxiv | 2024 | 38076958 | PubTator, text mining | PubMed |
| Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia. | Acta Haematol | 2024 | 38035547 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2122/papers?page=8